OTCPicks.com: CRRA, FRE, RTK, YMI, August 11 Stocks to Watch from OTCPicks.com

Tue. August 11, 2009; Posted: 04:44 AM

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

CAPITAL RESOURCE ALLIANCE INCORPORATED (OTCBB: CRRA | Quote | Chart | News | PowerRating) "Up 1,033.33% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CRRA.php

Capital Resource Alliance, Inc. engages in the acquisition and exploration of mineral properties in Canada. It holds 100% interest in the Long Lake property, which consists of 2 blocks of mineral claims comprising 21 units and is located in the Abrey Township, northwestern Ontario. The company intends to explore for economic reserves of gold, silver, and/or copper. Capital Resource Alliance, Inc. was founded in 2000 and is based in Calgary, Canada.

CRRA News:

August 10 - Capital Resource Alliance Announces Letter of Intent to Acquire Revolutionary New Building System

Mr. Frederick Fitzgerald, President and Chief Operating Officer of Capital Resource Alliance Inc. (OTCBB: CRRA | Quote | Chart | News | PowerRating) announced the acquisition of the principal assets of Engineered Construction Solutions Inc., of Calgary. Terms of the purchase are Forty Million shares of Capital Resource Alliance Inc. common stock at closing plus an undertaking to use every effort to supply up to $500,000 working capital on or before the closing date of October 31, 2009.

The purchased assets consist of all the proprietary technology and intellectual property involved with the manufacture and marketing of "WonderWall" a revolutionary building system that involves on site creation of long lasting, low cost housing, schools, commercial buildings and storage facilities. The foundation of the building components is a propriety ceramic foam manufactured on site, quickly and economically. The resultant building product is fire and water proof, virtually indestructible under normal conditions and extremely cost affective. Several foreign governments and commercial enterprises have indicated active interest in this new building technology.

Mr. Ray Gordon, President and CEO of Engineered Construction Solutions Inc. has agreed to join the Board of Capital Resource Alliance Inc. and assume the office of President and CEO of the purchasing corporation. Frederick Fitzgerald will remain as a director and retain his office of Secretary/Treasurer.

FREDDIE MAC (NYSE: FRE | Quote | Chart | News | PowerRating) "Up 128.38% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/FRE.php

Freddie Mac purchases residential mortgages and mortgage-related securities in the secondary mortgage market and securitizes them into mortgage-related securities that can be sold to investors. It operates in three segments: Investments, Single-family Guarantee, and Multifamily. The Investments segment invests primarily in mortgage-related securities and single-family mortgage loans; purchases mortgage loans and mortgage-related securities; and issues short- and long-term debt in the capital markets. The Single-Family Guarantee segment engages in the purchase of single-family mortgages in the primary mortgage market, primarily through its guarantor swap program; securitizes certain mortgages; issues mortgage-related securities that can be sold; and guarantees the payment of principal and interest on single-family mortgage-related securities. The Multifamily segment purchases multifamily mortgages; and guarantees the payment of principal and interest on multifamily mortgage-related securities and mortgages underlying multifamily housing revenue bonds. This segment also holds equity investments in various limited partnerships that sponsor low- and moderate-income multifamily rental apartments. The company primarily serves lenders in the primary mortgage market that originate mortgages for homeowners and apartment owners, including mortgage banking companies, commercial banks, savings banks, community banks, credit unions, state and local housing finance agencies, and savings and loan associations in the United States. Freddie Mac was founded in 1970 and is based in McLean, Virginia.

FRE News:

August 7 - Freddie Mac Releases Second Quarter 2009 Financial Results

Summary

* Net income for the second quarter of 2009 was $768 million. After the dividend payment of $1.1 billion to the U.S. Department of the Treasury on the senior preferred stock, net loss per diluted common share was $0.11 for the quarter.

* Net worth at June 30, 2009 was $8.2 billion. As a result of the positive net worth, no additional funding from the U.S. Department of the Treasury was required under the terms of the Senior Preferred Stock Purchase Agreement for the second quarter. The positive net worth includes a $5.1 billion increase to total equity reflecting the April 1, 2009 adoption of FSP FAS 115-2 and FAS 124-2 relating to accounting for security impairments.

The second quarter 2009 results were primarily driven by:

* Net interest income of $4.3 billion;

* Gains on the company's derivative portfolio and guarantee asset of $4.2 billion, mainly related to net mark-to-market gains due to increases in long-term interest rates;

* Net impairment of available-for-sale securities recognized in earnings of $2.2 billion, also reflecting the adoption of FSP FAS 115-2 and FAS 124-2; and

* Provision for credit losses of $5.2 billion.

* Freddie Mac continued to support the recovery of the housing market. During the second quarter of 2009, the company:

* Provided $171 billion of liquidity to the mortgage market, helping to finance more than 720,000 single-family homes and nearly 100,000 units of rental housing;

* Helped refinance approximately 28,500 loans under the Freddie Mac Relief Refinance Mortgage (SM); and

* Helped approximately 45,000 borrowers stay in their homes or sell their properties, including approximately 16,000 borrowers who were placed in trial period payment plans under the Home Affordable Modification program.

Freddie Mac (NYSE: FRE | Quote | Chart | News | PowerRating) reported net income of $768 million for the quarter ended June 30, 2009, compared to a net loss of $9.9 billion for the quarter ended March 31, 2009. After the dividend payment of $1.1 billion on its senior preferred stock to the U.S. Department of the Treasury (Treasury), Freddie Mac reported a net loss per diluted common share of $0.11 in the second quarter of 2009, compared to a net loss per diluted common share of $3.14 in the first quarter of 2009.

Freddie Mac had a positive net worth of $8.2 billion at June 30, 2009. As a result, no additional funding was required from Treasury under the terms of the Senior Preferred Stock Purchase Agreement (Purchase Agreement) for the second quarter.

"We are pleased that our financial results allowed us to finish the quarter with a positive net worth, meaning we will not need to request any additional financial support from the government at this time. However, we recognize that our financial results for the quarter include one-time accounting adjustments and mark-to-market gains that are subject to change in future periods," said Freddie Mac Interim Chief Executive Officer John Koskinen. "While we are seeing some early signs pointing to a housing recovery - including a modest uptick in house prices in some markets - our outlook remains cautious due to rising foreclosures, growing unemployment, tight lending standards and buyers' reluctance to re-enter the market.

"Our role in the Obama Administration's recovery efforts has been focused on helping to stem the foreclosure crisis. In the first half of the year, we were able to help more than 85,000 distressed borrowers avoid foreclosure, and we helped an additional 1 million homeowners lower their mortgage payments through refinancing. The Making Home Affordable program is ramping up and Freddie Mac employees are dedicated to working with our borrowers to help them understand their options and with our servicers to quickly increase their infrastructure and capacity.

"On another positive note, we look forward to welcoming our new CEO Ed Haldeman to Freddie Mac. I'm confident that under Ed's leadership we will continue to play a leading role in the recovery of the housing market, while building a stronger foundation for our future," Koskinen said.

RENTECH INCORPORATED (AMEX: RTK | Quote | Chart | News | PowerRating) "Up 112.90% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/RTK.php

Incorporated in 1981, Rentech provides clean energy solutions. The Rentech Process is a patented and proprietary technology that converts synthesis gas from biomass and fossil resources into hydrocarbons that can be processed and upgraded into ultra-clean synthetic fuels, specialty waxes and chemicals. Rentech Energy Midwest Corporation, the Company's wholly-owned subsidiary, manufactures and sells fertilizer products including ammonia, urea ammonia nitrate, urea granule and urea solution to the corn-belt region.

RTK News:

August 10 - Rentech Announces Record Earnings of 22 Cents per Share for Third Quarter of Fiscal 2009

Company Projects Positive EPS for FY 2009 and Increases Guidance for Consolidated and REMC EBITDA

Rentech, Inc. (Amex: RTK | Quote | Chart | News | PowerRating) announced results for its third quarter of fiscal year 2009 ended June 30. The Company also issued new guidance for consolidated earnings per share and increased previously provided financial guidance for the 2009 fiscal year.

For the third quarter of fiscal year 2009 ended June 30, Rentech reported net income applicable to common shareholders of $36.1 million, or $0.22 per share. This compares to a net loss applicable to common shareholders of $7.8 million, or $0.05 per share, for the comparable period in fiscal year 2008.

Rentech reported revenue of $91.4 million for the third quarter of fiscal year 2009, up from $60.4 million for the comparable quarter in the prior year. The increase resulted from higher product pricing and record shipments during the quarter as favorable weather conditions allowed the realization of revenue on significant volumes shipped. Shipments during the second fiscal quarter had been delayed by bad weather.

Rentech projects that its earnings per share will be positive for fiscal year 2009. Rentech is increasing its consolidated EBITDA guidance for fiscal year 2009 to greater than $25 million compared to previous guidance of $15 million. The Company has also increased fiscal year 2009 EBITDA guidance for its wholly-owned nitrogen fertilizer business, Rentech Energy Midwest Corporation (REMC), to greater than $65 million from previous guidance of $65 million. In addition to the strong results for the quarter, factors that the Company considered in increasing guidance included: significant pre-sales of fertilizer products for the remainder of the fiscal year; natural gas prices that are forecasted to remain at lower than budgeted levels; and demand for nitrogen products driven by continued strong prospects for planted corn acreage. EBITDA is a non-GAAP measure. Further explanation of this non-GAAP measure and a computation of consolidated EBITDA and EBITDA at REMC have been included below in this press release.

Selling, general and administrative (SG&A) expenses were $6.0 million for the third quarter of fiscal year 2009, down from $8.3 million for the third quarter of the prior year. Research and development (R&D) expenses for the third quarter of fiscal year 2009 were $7.2 million, down from $15.8 million for the third quarter of the prior year. The decrease in R&D expenses was primarily due to the completion of construction of the Company's Product Demonstration Unit (PDU) in the prior fiscal year. Current period R&D expenses were attributable to costs associated with operating the PDU, expenses incurred for work on advanced catalysts, catalyst separation from crude wax, process optimization, and product upgrading. R&D expenses for the current period also included a one-time tax accrual of $2.9 million related to the construction of the PDU.

Rentech reported revenue of $158.3 million for the nine months ended June 30, 2009, compared to $136.4 million for the comparable period in the prior year. SG&A expenses were $18.7 million for the first nine months of fiscal year 2009, down from $26.1 million for the comparable period in the prior year. R&D expenses for the current period were $16.6 million, down from $53.9 million for the comparable period in the prior year. As noted previously, the decrease was primarily due to the completion of construction of the PDU in the prior fiscal year.

As of June 30, 2009, Rentech had cash and cash equivalents of $38.9 million on a consolidated basis.

Commenting on the third quarter results for fiscal year 2009, Dan Cohrs, Executive Vice President and CFO of Rentech, stated, "We are pleased to report our first profitable quarter ever. The cost reductions we implemented in addition to exceptional management of our fertilizer business have provided us with a foundation from which we can continue to execute on our alternative energy strategy."

Mr. Cohrs continued, "We believe Rentech is well-positioned to capture the opportunities that have resulted from the approval of our jet fuel for commercial aviation as well as from the renewable power and low carbon fuel mandates in California."

The Company will hold a conference call on Tuesday, August 11, at 10:00 a.m. PDT at which time Rentech's senior management will review the Company's financial results for this period and provide an update on corporate developments. Callers may listen to the live presentation, which will be followed by a question and answer segment, by dialing 800-926-9801 or 212-231-2903. An audio webcast of the call will be available at www.rentechinc.com within the Investor Relations portion of the site under the Presentations section. A replay will be available by audio webcast and teleconference from 1:00 p.m. PDT on August 11 through 1:00 p.m. PDT on August 18. The replay teleconference will be available by dialing 800-633-8284 or 402-977-9140 and the reservation number 21432611.

YM BIOSCIENCES INCORPORATED (AMEX: YMI | Quote | Chart | News | PowerRating) "Up 58.59% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/YMI.php

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody, and AeroLEF , a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

YMI News: August 10 - YM Biosciences USA Receives Clearance From Us Treasury Department to Extend Clinical Program for Nimotuzumab

YM BioSciences Inc. (Amex: YMI | Quote | Chart | News | PowerRating) (TSX: YM, AIM: YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) has received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to further develop its lead product, nimotuzumab, for patients with solid tumor cancers in the United States.

"This license from OFAC to develop nimotuzumab in any cancer indication is a major step forward in our US development program and will allow us to immediately discuss our IND submissions with the FDA to include US patients in our randomized, double-blinded lung cancer and brain metastases trials," said David Allan, Chairman and CEO of YM BioSciences. "Our development plans may also include extending some of the Phase III trials being conducted worldwide into the US. There are quantifiable physical, emotional and financial costs that result from the numerous and severe toxicities of the currently available EGFR-targeting drugs which are not evident with the administration of our drug. Nimotuzumab has been demonstrating efficacy in trials throughout the world and we are very pleased that US patients will now have the opportunity to receive the drug and that a broader group of US oncologists will gain experience with it. Our goal is to bring this therapeutic option, already approved for marketing in 18 countries, to patients in the US as rapidly as possible."

Mr. Allan added, "We have also applied to OFAC for a license to make nimotuzumab available to US patients upon marketing approval by the FDA. This is consistent with a 2009 Staff Report to the US Senate Committee on Foreign Relations (SCFR) entitled 'Changing Cuba Policy - In the United States' National Interest,' which recommended pharmaceutical imports from Cuba's rapidly developing biotech industry. We are most appreciative of the extensive support we have received for our application from SCFR Chairman Senator John Kerry (D-MA), Western Hemisphere Subcommittee Chairman Senator Chris Dodd (D-CT) and SCFR Ranking Member Senator Richard Lugar (R-IN) and for their acute understanding of the needs of cancer patients. Such licenses have been previously granted to two companies seeking to commercialize Cuban-origin therapeutics in the US and we have ongoing discussions with OFAC in this regard."

YM USA previously received a license from OFAC to import nimotuzumab into the US to conduct a study of nimotuzumab in children suffering from recurrent diffuse intrinsic pontine glioma. This trial is ongoing at 10 of the principal oncology hospitals in the US and data is expected in 2010. Nimotuzumab is also available on a compassionate use basis in the US for children with this condition and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. The drug has demonstrated efficacy in clinical trials without the serious side effects observed with the marketed EGFR-targeting drugs. Nimotuzumab has been administered to approximately 5,000 patients worldwide and is currently in 32 trials internationally of which 11 are being conducted by YM and its four licensees. Three of the latter are Phase III trials, including one being conducted by the internationally recognized National Cancer Center of Singapore, which selected nimotuzumab over the alternative antibodies because of its benign side effect profile.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for CRRA click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index